Despite the increasing sophistication of anticancer therapies, many malignancies continue to evade treatment. T cells expressing chimeric antigen receptor (CAR) can effectively attack some tumors by recognizing antigens expressed on the tumor surface, but the therapy may prove ineffective if the target antigen is not abundant enough throughout the tumor.
Diabetic retinopathy (DR) is a leading cause of vision loss in patients with diabetes, with limited therapeutic options. While current treatments focus on the proliferative stage, there is an urgent need to understand the underlying mechanisms of the early stages of DR to halt progression. Growing research suggests that activated microglia are key drivers of inflammation in DR.
A team of researchers from the University of Castilla-La Mancha, Spain, further investigated the link between hippocampal G protein-activated inward rectifier potassium channel (GIRK) and Alzheimer’s disease pathology.
As of May 2023, the WHO recommends the use of a monovalent XBB.1 descendent lineage, such as omicron XBB.1.5, as the vaccine antigen for COVID-19 vaccines. However, BA.2.86 and its descendent lineages, such as JN.1, have emerged and rapidly spread worldwide.
Single agonists of the glucagon-like peptide-1 receptor (GLP-1R) have been a success in the treatment of obesity, but monomeric dual or triple agonists have demonstrated improved efficacy on energy intake, appetite or metabolic function.
Oxyntomodulin (OXM) is a peptide hormone released by intestinal L cells after food intake. It acts as a dual agonist of glucagon-like peptide 1 (GLP-1) and glucagon receptors, regulating appetite, energy expenditure and glucose metabolism. However, its short plasma half-life limits its therapeutic potential.
Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease with limited treatment options. IPF is thought to result from repeated microinjuries to aging lung tissue, triggering dysfunctional repair responses that drive fibrosis and respiratory failure. Researchers from the University of Wisconsin Madison and the University of Texas Medical Branch have now identified a potential new therapeutic approach for IPF by targeting bromodomain-containing protein 4 (BRD4).
“Loss of synapses and dysfunctional synapses in a region-specific way is important in Alzheimer’s. It’s actually the strongest correlate of cognitive decline, far more so than plaques and tangles, which are the pathological hallmarks,” Soyon Hong told the audience at the XVII Meeting on Glial Cells in Health and Disease, which was held in Marseille last week.
RSS
